Lymphocyte muscarinic cholinergic activity and PGE2 involvement in experimental Trypanosoma cruzi infection. NLM AIDSLINE Important note: Information in this article was accurate in 1997. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Lymphocyte muscarinic cholinergic activity and PGE2 involvement in experimental Trypanosoma cruzi infection.

Clin Immunol Immunopathol. 1996 Nov;81(2):122-8. Unique Identifier : AIDSLINE MED/97064123
Sterin-Borda L; Gorelik G; Goren N; Cappa SG; Celentano AM; Borda E; CEFYBO-CONICET, Catedras de Microbiologia y Farmacologia,; Facultad de Medicina y de Odontologia, Universidad de Buenos; Aires, Argentina.

Abstract: In this paper, we demonstrated that the production of PGE2 by CD8+ T lymphocytes through muscarinic cholinergic receptor (mAChR) activation of lymphocytes from mice acutely infected with nonlethal Trypanosoma cruzi CA-1 strain could enhance resistance to infection. Treatment in vivo with either atropine or cyclooxygenase inhibitors enhanced mortality rates and parasitemia of mice infected with T. cruzi CA-1 strain. The mechanism by which CD8+ T lymphocytes released PGE2 appears to involve the activation of the cells by circulating IgG present in mice infected with T. cruzi CA-1 strain. Binding of these antibodies to mAChR on CD8+ T lymphocytes triggered the release of large amounts of PGE2. The results point to a role of serum antibodies against mAChR in the protection of T. cruzi infection. The prostanoid acting as an immunomodulator contributed to the maintenance of the chronic course of experimental Chagas disease.
Keywords: Adjuvants, Immunologic/*PHARMACOLOGY Animal Atropine/PHARMACOLOGY Cell Membrane/PARASITOLOGY Chagas Disease/BLOOD/*IMMUNOLOGY CD8-Positive T-Lymphocytes/*CHEMISTRY Dinoprostone/BLOOD/*PHARMACOLOGY IgG/METABOLISM Immunity, Natural Male Mice Mice, Inbred BALB C Muscarinic Antagonists/PHARMACOLOGY Receptors, Cholinergic/IMMUNOLOGY/*METABOLISM Receptors, Muscarinic/IMMUNOLOGY/*METABOLISM T-Lymphocytes/METABOLISM Trypanosoma cruzi/ISOLATION & PURIF JOURNAL ARTICLEKWDadjuvants,immunologic/KWDpharmacologyanimalatropine/pharmacologycellmembrane/parasitologychagasdisease/blood/KWDimmunologycd8-positivet-lymphocytes/KWDchemistrydinoprostone/blood/KWDpharmacologyigg/metabolismimmunity,naturalmalemicemice,inbredbalbcmuscarinicantagonists/pharmacologyreceptors,cholinergic/immunology/KWDmetabolismreceptors,muscarinic/immunology/KWDmetabolismt-lymphocytes/metabolismtrypanosomacruzi/isolation&purifjournalarticle
970228
M9721898

Copyright © 1997 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1997. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1997. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .